Galunisertib [700874-72-2]
Katalog-Nummer T2510-10mg
Size : 10mg
Marke : TargetMol
Galunisertib
Contact us for more batch information
Purity:100%
Resource Download
COA HPLC HNMR
Galunisertib
Catalog No. T2510Cas No. 700874-72-2
Galunisertib (LY2157299) is an orally available inhibitor of TGFβRI kinase (IC50: 56 nM) with potential antineoplastic activity.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. Pack Size | ||
---|---|---|
5 mg | In Stock | |
10 mg | In Stock | |
25 mg | In Stock | |
50 mg | In Stock | |
100 mg | In Stock | |
200 mg | In Stock | |
500 mg | In Stock | |
1 g | In Stock | |
1 mL x 10 mM (in DMSO) | In Stock |
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
Description | Galunisertib (LY2157299) is an orally available inhibitor of TGFβRI kinase (IC50: 56 nM) with potential antineoplastic activity. |
In vitro | The HCC cell lines were simultaneously exposed to 0.1, 1, 10, and 100 μM galunisertib (LY-2157299) with 5 μM sorafenib in presence of TGF-β for 72 hours. Galunisertib displayed a slight dose-dependent potentiation of sorafenib in SK-Sora, HepG2, and Hep3B cell lines but not in JHH6, SK-HEP1, and HuH7 cell lines [2]. Leukemic cells (K562) and marrow stromal cells (HS-5) were treated with TGF-β1 (20 ng/ml) in the presence and absence of LY-2157299 (5 μM) and assessed for SMAD2 phosphorylation by immunoblotting. LY-2157299 pretreatment (1 hr) led to attenuation of activation/phosphorylation of SMAD2 [3]. |
In vivo | Mice transgenic for alb/TGF-β were treated with either LY-2157299 (100 mg/kg/d) or vehicle daily by gastric lavage for 14 days. Blood counts were done on the 14th day and revealed a significant rise in hematocrit after LY-2157299 treatment. The mice were sacrificed and bone marrow biopsies were immunostained with an antibody against phosphor-SMAD2. Representative sample shows inhibition of SMAD2 activation after LY-2157299 treatment [3]. After oral administration of 75 mg/kg, LY2157299 induced a 70% decrease in pSmad for both types of cell lines. The time at which pSmad recovered 80% of baseline was approximately 6 h after administration [4]. |
Kinase Assay | Briefly, the assay was first done at 30°C for 4 h in a 96-well plate containing 2 ng/mL TGF-bR KD, 100 mM Hepes pH 7.5, 4 mM MgCl2, 0.2 mM MnCl2, 0.4 mM sodium orthovanadate, 2 mM DL-dithiothreitol, and 10mM ATP. After incubation, 50mL of Kinase-Glo plus reagent was added and further incubated at 25°C for 30 min. Subsequently, a 100mL aliquot of each reaction mixture was transferred to a black mictotiter plate and the luminescence was measured by a vector counter. The inhibitory activity IC50 was tested in duplicate for each sample [1]. |
Cell Research | Cell survival was determined using the MTT assay. The conversion of yellow water-soluble tetrazolium MTT into purple insoluble formazan is catalyzed by mitochondrial dehydrogenases and used to estimate the number of viable cells. In brief, cells were seeded in 96-well tissue culture plates at a density of 2 × 103 cells/well. After drug exposure, cells were incubated with 0.4 mg/mL MTT for 4 hours at 37°C. After incubation, the supernatant was discarded, insoluble formazan precipitates were dissolved in 0.1 mL of DMSO, and the absorbance was measured at 560 nm by use of a microplate reader. Wells with untreated cells or with drug-containing medium without cells were used as positive and negative controls respectively. For proliferation assay, MTT assay was done daily to determine the number of viable cells in untreated control and galunisertib-treated group [2]. |
Animal Research | Transgenic mice expressing a fusion gene (Alb/TGF) consisting of modified porcine TGF-β1 cDNA under the control of the regulatory elements of the mouse albumin gene (26) were used under animal institute approved protocol. Mice were given LY-2157299 at a dose of 100mg/kg/day in NaCMC/SLS/PVP/antifoam solution by gastric lavage using a curved 14 G needle. Blood counts were analyzed by the Advia machine. Mice femurs were flushed and bone marrows cells were used for clonogenic assays [3]. |
Alias | LY2157299 |
Molecular Weight | 369.42 |
Formula | C22H19N5O |
Cas No. | 700874-72-2 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (135.35 mM) 5% DMSO+95% Saline: 3.45 mg/mL (9.34 mM, precipitation) Ethanol: Insoluble | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMSO/5% DMSO+95% Saline
DMSO
|
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
inhibitLY 2157299Transforming growth factor beta receptorsInhibitorLY-2157299TGF-β ReceptorGalunisertib